BACKGROUND: There is increasing interest in the role of immune activation and inflammation in HIV disease, but data on direct effects of HIV replication on immune cell activation are limited. METHODS: High sensitivity multiplex bead array assays (MBAAs) were used to measure changes in plasma cytokines and chemokines [interleukin (IL)-1β, IL-2, IL-6, IL-7, IL-8, IL-12p70, IL-17, tumor necrosis factor-α (TNFα), interferon-γ, granulocyte macrophage colony-stimulating factor, IL-4, IL-5, IL-10, IL-13, CXCL10] from randomization (month 0) to month 2 in a random sample of 200 patients from both the drug conservation (DC) and viral suppression (VS) arms of the Strategies for Management of Antiretroviral Therapy (SMART) trial. IL-6 was also measured by ELISA. Data were evaluated using nonparametric correlation and censored parametric analysis of covariance and associations were declared as statistically significant when the Bonferroni-adjusted P-value was less than 0.003. RESULTS: Compared with the VS arm, significant increases were seen in the DC arm for TNFα (+0.34 log(e) pg/ml, P = 0.0001), IL-10 (+0.33 log(e) pg/ml, P = 0.00001) and CXCL10 (+0.66 log(e) pg/ml, P = 0.00001). IL-6 ELISA poorly correlated with IL-6 MBAA (Spearman's rho = 0.29, P = 0.0001). CONCLUSION: Resumption of HIV replication after ceasing antiretroviral therapy is associated predominantly with an increase of monocyte/macrophage-derived cytokines. Measurement of IL-6 levels may be affected by assay method and this should be considered in future studies of biomarkers.
BACKGROUND: There is increasing interest in the role of immune activation and inflammation in HIV disease, but data on direct effects of HIV replication on immune cell activation are limited. METHODS: High sensitivity multiplex bead array assays (MBAAs) were used to measure changes in plasma cytokines and chemokines [interleukin (IL)-1β, IL-2, IL-6, IL-7, IL-8, IL-12p70, IL-17, tumor necrosis factor-α (TNFα), interferon-γ, granulocyte macrophage colony-stimulating factor, IL-4, IL-5, IL-10, IL-13, CXCL10] from randomization (month 0) to month 2 in a random sample of 200 patients from both the drug conservation (DC) and viral suppression (VS) arms of the Strategies for Management of Antiretroviral Therapy (SMART) trial. IL-6 was also measured by ELISA. Data were evaluated using nonparametric correlation and censored parametric analysis of covariance and associations were declared as statistically significant when the Bonferroni-adjusted P-value was less than 0.003. RESULTS: Compared with the VS arm, significant increases were seen in the DC arm for TNFα (+0.34 log(e) pg/ml, P = 0.0001), IL-10 (+0.33 log(e) pg/ml, P = 0.00001) and CXCL10 (+0.66 log(e) pg/ml, P = 0.00001). IL-6 ELISA poorly correlated with IL-6 MBAA (Spearman's rho = 0.29, P = 0.0001). CONCLUSION: Resumption of HIV replication after ceasing antiretroviral therapy is associated predominantly with an increase of monocyte/macrophage-derived cytokines. Measurement of IL-6 levels may be affected by assay method and this should be considered in future studies of biomarkers.
Authors: Robert C Kalayjian; Rhoderick N Machekano; Nesrine Rizk; Gregory K Robbins; Rajesh T Gandhi; Benigno A Rodriguez; Richard B Pollard; Michael M Lederman; Alan Landay Journal: J Infect Dis Date: 2010-06-15 Impact factor: 5.226
Authors: Sonia Fernandez; Ann A Rosenow; Ian R James; Steven G Roberts; Richard C Nolan; Martyn A French; Patricia Price Journal: J Acquir Immune Defic Syndr Date: 2006-01-01 Impact factor: 3.731
Authors: Philip J Norris; Brandee L Pappalardo; Brian Custer; Gerald Spotts; Frederick M Hecht; Michael P Busch Journal: AIDS Res Hum Retroviruses Date: 2006-08 Impact factor: 2.205
Authors: Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek Journal: J Infect Dis Date: 2011-01-20 Impact factor: 5.226
Authors: Craig M Wilson; Jonas H Ellenberg; Steven D Douglas; Anna-Barbara Moscicki; Christie A Holland Journal: AIDS Res Hum Retroviruses Date: 2004-03 Impact factor: 2.205
Authors: Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Jacqueline Neuhaus; Daniel Nixon; Nicholas I Paton; James D Neaton Journal: PLoS Med Date: 2008-10-21 Impact factor: 11.069
Authors: Philip M Grant; Lauren Komarow; Alejandro Sanchez; Fred R Sattler; David M Asmuth; Richard B Pollard; Andrew R Zolopa Journal: HIV Clin Trials Date: 2014 Jul-Aug
Authors: Daniel W Fitzgerald; Karl Bezak; Oksana Ocheretina; Cynthia Riviere; Thomas C Wright; Ginger L Milne; Xi Kathy Zhou; Baoheng Du; Kotha Subbaramaiah; Erin Byrt; Matthew L Goodwin; Arash Rafii; Andrew J Dannenberg Journal: Cancer Prev Res (Phila) Date: 2011-12-01
Authors: Martyn A French; Alessandro Cozzi-Lepri; Roberto C Arduino; Margaret Johnson; Amit C Achhra; Alan Landay Journal: AIDS Date: 2015-04-24 Impact factor: 4.177
Authors: Rachel P Simmons; Eileen P Scully; Erin E Groden; Kelly B Arnold; J Judy Chang; Kim Lane; Jeff Lifson; Eric Rosenberg; Douglas A Lauffenburger; Marcus Altfeld Journal: AIDS Date: 2013-10-23 Impact factor: 4.177
Authors: D Heather Watts; Paige L Williams; Deborah Kacanek; Raymond Griner; Kenneth Rich; Rohan Hazra; Lynne M Mofenson; Hermann A Mendez Journal: J Infect Dis Date: 2012-11-29 Impact factor: 5.226
Authors: Philip M Grant; Lauren Komarow; Michael M Lederman; Savita Pahwa; Andrew R Zolopa; Janet Andersen; David M Asmuth; Sridevi Devaraj; Richard B Pollard; Aaron Richterman; Sudheesh Kanthikeel; Irini Sereti Journal: J Infect Dis Date: 2012-09-21 Impact factor: 5.226